TG Therapeutics, Inc. (TGTX): Price and Financial Metrics

TG Therapeutics, Inc. (TGTX): $14.63

0.48 (+3.39%)

POWR Rating

Component Grades













Add TGTX to Watchlist
Sign Up

Industry: Biotech



in industry


  • TGTX scores best on the Growth dimension, with a Growth rank ahead of 74.61% of US stocks.
  • The strongest trend for TGTX is in Value, which has been heading down over the past 177 days.
  • TGTX ranks lowest in Stability; there it ranks in the 0th percentile.

TGTX Stock Summary

  • TG THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 11.09% of US listed stocks.
  • TGTX's price/sales ratio is 409.27; that's higher than the P/S ratio of 99.01% of US stocks.
  • With a year-over-year growth in debt of 209.85%, TG THERAPEUTICS INC's debt growth rate surpasses 93.2% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to TG THERAPEUTICS INC, a group of peers worth examining would be CRBU, RXRX, ADAP, MCRB, and AGLE.
  • Visit TGTX's SEC page to see the company's official filings. To visit the company's web site, go to

TGTX Valuation Summary

  • TGTX's EV/EBIT ratio is -7.7; this is 177.78% lower than that of the median Healthcare stock.
  • Over the past 155 months, TGTX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for TGTX.

Stock Date P/S P/B P/E EV/EBIT
TGTX 2023-01-20 356.9 17.8 -7.5 -7.7
TGTX 2023-01-19 341.9 17.1 -7.2 -7.3
TGTX 2023-01-18 344.5 17.2 -7.3 -7.4
TGTX 2023-01-17 372.5 18.6 -7.8 -8.0
TGTX 2023-01-13 394.2 19.7 -8.3 -8.5
TGTX 2023-01-12 381.8 19.1 -8.0 -8.2

TGTX Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -104.96%.
  • The 5 year cash and equivalents growth rate now stands at -44.6%.
  • Its 3 year price growth rate is now at -14.55%.
TGTX's revenue has moved up $4,872,619 over the prior 67 months.

The table below shows TGTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 5.025 -239.209 -238.679
2022-06-30 6.961 -271.915 -288.498
2022-03-31 7.912 -282.968 -326.485
2021-12-31 6.689 -295.634 -348.101
2021-09-30 4.406 -260.751 -342.98
2021-06-30 2.414 -250.082 -344.506

TGTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TGTX has a Quality Grade of D, ranking ahead of 7.5% of graded US stocks.
  • TGTX's asset turnover comes in at 0.005 -- ranking 411th of 681 Pharmaceutical Products stocks.
  • TMBR, ATRA, and EVOK are the stocks whose asset turnover ratios are most correlated with TGTX.

The table below shows TGTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 0.881 -27.668
2021-03-31 0.002 0.847 -42.516
2020-12-31 0.000 1.000 -36.140
2020-09-30 0.001 1.000 -86.159
2020-06-30 0.001 1.000 -22.399
2020-03-31 0.001 1.000 -12.310

TGTX Price Target

For more insight on analysts targets of TGTX, see our TGTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.33 Average Broker Recommendation 1.44 (Moderate Buy)

TGTX Stock Price Chart Interactive Chart >

Price chart for TGTX

TGTX Price/Volume Stats

Current price $14.63 52-week high $14.85
Prev. close $14.15 52-week low $3.48
Day low $13.71 Volume 4,000,500
Day high $14.85 Avg. volume 5,745,900
50-day MA $9.97 Dividend yield N/A
200-day MA $7.10 Market Cap 2.13B

TG Therapeutics, Inc. (TGTX) Company Bio

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company was founded in 1993 and is based in New York, New York.

TGTX Latest News Stream

Event/Time News Detail
Loading, please wait...

TGTX Latest Social Stream

Loading social stream, please wait...

View Full TGTX Social Stream

Latest TGTX News From Around the Web

Below are the latest news stories about TG THERAPEUTICS INC that investors may wish to consider to help them evaluate TGTX as an investment opportunity.

TG Therapeutics' (NASDAQ:TGTX) investors will be pleased with their 26% return over the last five years

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...

Yahoo | January 18, 2023

TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know

TG Therapeutics (TGTX) closed at $13.20 in the latest trading session, marking a +0.61% move from the prior day.

Yahoo | January 12, 2023

TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Yahoo | January 12, 2023

TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | January 9, 2023

TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PTNEW YORK, Jan. 06, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis, in San Francisco, CA. The presentation is scheduled to take place on Monday, January 9, 2023, at 9:45 AM PT. A live webcast of this presentation will be availa

Yahoo | January 6, 2023

Read More 'TGTX' Stories Here

TGTX Price Returns

1-mo 40.67%
3-mo 155.77%
6-mo 164.08%
1-year 50.36%
3-year 0.76%
5-year 19.43%
YTD 23.67%
2022 -37.74%
2021 -63.48%
2020 368.65%
2019 170.73%
2018 -50.00%

Continue Researching TGTX

Want to see what other sources are saying about Tg Therapeutics Inc's financials and stock price? Try the links below:

Tg Therapeutics Inc (TGTX) Stock Price | Nasdaq
Tg Therapeutics Inc (TGTX) Stock Quote, History and News - Yahoo Finance
Tg Therapeutics Inc (TGTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7318 seconds.